Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study
Autore:
Berk, M; Ichim, C; Brook, S;
Indirizzi:
Univ Witwatersrand, Sch Med, Dept Psychiat, ZA-2193 Johannesburg, South Africa Univ Witwatersrand Johannesburg South Africa ZA-2193 sburg, South Africa
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 16, anno: 2001,
pagine: 87 - 92
SICI:
0268-1315(200103)16:2<87:EOMAOT>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPSYCHOTIC-DRUGS; INDUCED CATALEPSY; FLUOXETINE; CLOZAPINE; AUGMENTATION; RECEPTORS; PROLACTIN; RATS;
Keywords:
haloperidol; mirtazapine; negative symptoms; schizophrenia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Berk, M Univ Witwatersrand, Sch Med, Dept Psychiat, 7 York Rd, ZA-2193 Johannesburg, South Africa Univ Witwatersrand 7 York Rd Johannesburg South Africa ZA-2193 ca
Citazione:
M. Berk et al., "Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study", INT CLIN PS, 16(2), 2001, pp. 87-92

Abstract

The negative symptoms of schizophrenia remain a major clinical challenge. Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects. Many ofthese pharmacological actions have clinical or preclinical evidence of efficacy in schizophrenia. This study was a 6-week randomized placebo-controlled trial of mirtzepine or placebo add on to haloperidol 5 mg in the treatment of 30 patients with DSM-IV schizophrenia. The primary finding of the trial was a 42% reduction in Positive and Negative Syndrome Scale (PANSS) negative symptom scores in the mirtazapine group compared to placebo at the endof 6 weeks (mirtazapine 13.9, SD 1.56; placebo 23.9, SD 1.56; P = 0.000, F= 20.31, d.f. = 1). The PANNS total scores, Clinical Global Impression severity and improvement scales in addition showed superiority of mirtazapine over placebo. There was no difference between the groups on the Hamilton depression scale at endpoint, suggesting that the improvement in negative symptoms was not an artifact of mood improvement. These results suggest a potential role for mirtazapine in the negative symptoms of schizophrenia. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 07:35:18